Tania Sultana, PhD ✍️’s Post

Stroke Thrombectomy vs. Medical Treatment at 1 Year Within 12 hours & established infarct: 1. Overall survival 55% vs. 38% 2. Moderate outcome 34% vs. 17% 3. Independent outcome 22% vs. 6% And importantly: ↳ Better quality of life (at 12 months) ✌️ From our TENSION Study (Lancet Neurology) (Repost ♻️ these important Stroke Trial results) P.S. Are you treating Low-ASPECTS patients? --- ✅ Join for More Updates Prof. Dr. Panagiotis Papanagiotou

February 29 is #RareDiseaseDay. Learn more about rare diseases in neurology through CNSA's Clinical Proceedings series ▶️ https://bit.ly/3a2xoEh

Results from our Phase 2 Vivacity-MG study evaluating nipocalimab in adults with moderate-to-severe generalized myasthenia gravis were published in Neurology by the American Academy of Neurology. These results reinforce our path to progress in offering safer, more effective and tolerable treatment options to people living with this rare autoantibody disease of the nervous system.   I want to extend my gratitude to our dedicated research team and to our clinical trial participants, without whom we could not advance the science towards better therapeutics. Access the article here: https://bit.ly/3NCoRZp #MyCompany #MyastheniaGravis

We are proud to present our latest data at the European Academy of Neurology 2024 Meeting. Significant unmet need remains for patients living with generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). This is why we're working to develop new treatment options for these conditions, with the goal of providing patients with symptom-free remission. To learn more about our rapidly evolving understanding of the immune system, visit our website: https://lnkd.in/eri7dwHY #EAN2024 #JNJNeuroscience #JNJImmunology

Intense basics of neurology Session 5: 13/06/2024 Topics: 1. The neurotransmitters and its disease. 2. The reflex action. 3. Classification of reflexes. 4. Reflex Applications: Vojta Therapy and Rood's fecilitation Timing: 8:20pm-9:35pm

If your practice is conducting neurology trials and you'd like to join an industry leading site network to optimize the success of your research studies, contact Tekton Research today. Combine your expertise with Tekton's experience and resources to propel new advancements in Alzheimer's, Parkinson's, MS, and other CNS indications. Let's work together! Contact us at letsmeet@tektonresearch.com #ClinicalResearch #ClinicalTrials #AlzheimersResearch

Intense basics of neurology Session 11: 21/06/2024 Topics: 1. Introduction to spinal cord 2. Spinal cord tracts Timing: 7:30pm-8:20pm 3. Spinal cord Injuries Timing: 8:40pm-9:30pm

Sharing some groundbreaking findings from the PROMISE trial published in The Lancet Neurology in March 2024! 🌟 This extensive study has shed new light on managing myasthenia gravis (MG), a chronic autoimmune disorder. The trial compared two key players in MG treatment: azathioprine (AZA) and mycophenolate mofetil (MMF). Here's the exciting part: MMF showed a faster path to improvement, with patients experiencing quicker relief and fewer side effects compared to AZA. While AZA was effective, it came with a higher risk of adverse effects like hepatotoxicity, making MMF a more attractive option for many patients. What's the clinical takeaway? MMF could become the go-to treatment for MG due to its rapid efficacy and better safety profile. Plus, the trial hints that lower doses of AZA might still pack a punch while reducing unwanted side effects. These insights are game-changers for clinicians and patients alike, paving the way for more tailored, effective, and safer MG treatments. As we continue to explore and refine these therapies, the future looks promising for those battling this challenging condition. Let's continue to push the boundaries of medical research and bring hope to more patients worldwide! 💪🔬 #Neurology #MyastheniaGravis #MedicalResearch #HealthcareInnovation #ClinicalTrials

Can't we increase not find a solid state electrolyte that would act as a reducer for depolarization of cell membrane like the new lithium batteries? I don't really know anything about science, but I like to imagine possibilities. 😀 #houseoflovingawareness #coloradomentalwellnessinitiative #willojontv #neurology #science #mentalhealth #mentalhealthmatters #mentalwellness #americanspiritsthemovie

The disability score of patients with neuromyelitis optica spectrum disorder (NMOSD) remains high at treatment follow-up, according to a new study published in the journal Multiple Sclerosis and Related Disorders Journal. This finding “highlights the importance of early diagnosis and management to optimize patient outcomes,” according to the study authors. To describe the wide clinical spectrum of NMOSD, a team of researchers from the National Institute of Neurology in Tunis, Tunisia, retrospectively analyzed data about the disease between 2015 and 2023. Read more: https://brnw.ch/21wG4tX #RareDisease